<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01614431</url>
  </required_header>
  <id_info>
    <org_study_id>Cystinosis and NAC</org_study_id>
    <nct_id>NCT01614431</nct_id>
  </id_info>
  <brief_title>N Acetyl Cysteine for Cystinosis Patients</brief_title>
  <official_title>N Acetyl Cysteine Can Decrease the Progression of Renal Disease in Cystinosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <brief_summary>
    <textblock>
      This study intends to verify the interference of N acetyl cysteine in the progression of
      chronic kidney disease in patients with Nephropathic Cystinosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with Nephropathic Cystinosis have an increased oxidative stress and go to end-stage
      renal disease, even when all steps of the treatment are done. Therefore, this study is
      conducted to verify the interference of the stress oxidative in the progression of the renal
      disease with the use of an oxidant drug, N acetyl cysteine (NAC). The investigators selected
      patients with good compliance of the treatment. In these patients the investigators evaluate
      the serum creatinine, creatinine clearance estimated by Schwartz Formula, cystatin C and a
      marker of oxidative stress, TBARS ( thiobarbituric acid substances). The variables are
      analyzed 6 months before the introduction of NAC and the three months after NAC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>creatinine clearance</measure>
    <time_frame>change in creatinine clearance evaluated 6 months before , at baseline and after 3 months with NAC</time_frame>
    <description>creatinine clearance will be evaluate 6 months beforw and at baseline and after 3 months with NAC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cystatin c</measure>
    <time_frame>change in cystatin C from baseline and after 3 months with NAC</time_frame>
    <description>Cystinosis patients will be evaluated 6 months before and at baseline and after 3 months after the use of NAC</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Renal Disease</condition>
  <condition>Cystinosis</condition>
  <arm_group>
    <arm_group_label>N acetyl cysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NAC will be given to cystinosis patients and we will observe the renal function status and a marker of oxidative stress (TBARS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N acetyl cysteine</intervention_name>
    <description>N acetyl cysteine to cystinosis patients with CKD stages 1 to 4</description>
    <arm_group_label>N acetyl cysteine</arm_group_label>
    <other_name>N acety cysteine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N acetyl cysteine</intervention_name>
    <description>N acetyl cysteine for cystinosis patients CKD stages 1 to 4</description>
    <arm_group_label>N acetyl cysteine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cystinosis patients age under 18 years with good compliance to the treatment with
             Chronic Kidney Disease 1 to 4 according to KDOQI

        Exclusion Criteria:

          -  patients with CKD stage 5
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Helena Vaisbich, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2012</study_first_submitted>
  <study_first_submitted_qc>June 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2012</study_first_posted>
  <last_update_submitted>June 19, 2012</last_update_submitted>
  <last_update_submitted_qc>June 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Maria Helena Vaisbich</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>renal function</keyword>
  <keyword>before and after N acetyl cysteine</keyword>
  <keyword>Cystinosis patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Cystinosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

